GHRP-2: The parent compound and its metabolites are detectable in urine for up to 47 hours after nasal administration
The primary mechanism involves activation of the VEGFR2-Akt-eNOS pathway
C62H98N16O22
Laboratory research has examined its interaction with nitric oxide (NO) pathways, growth factor modulation including VEGF and EGF, and the FAK-paxillin signaling cascade used in tissue remodeling studies
At the same time, there is abnormal activity of osteoclasts, enhanced bone resorption, slow loss of bone mass, accompanied by thinning and fracture of bone trabeculae and thinning of cortical bone
This monitoring serves three purposes: confirming that your stack is producing the intended biochemical effects, ensuring safety by tracking organ function and metabolic markers, and providing the data needed to optimize your protocol over time